Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Item
http://www.wikidata.org/entity/Q35637346
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsSystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionZidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.New and emerging agents in the management of lipodystrophy in HIV-infected patients.The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspectiveRegional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophyTreatment options for lipodystrophy in HIV-positive patients.Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.Body-fat abnormalities in patients with HIV: progress and challenges.Cardiovascular complications in HIV management: past, present, and future.From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals.Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil.
P2860

Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Item
http://www.wikidata.org/entity/Q35637346
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Switching to a protease inhibi ...... S clinical trial group 5125s).
@ast
Switching to a protease inhibi ...... S clinical trial group 5125s).
@en
type
label
Switching to a protease inhibi ...... S clinical trial group 5125s).
@ast
Switching to a protease inhibi ...... S clinical trial group 5125s).
@en
prefLabel
Switching to a protease inhibi ...... S clinical trial group 5125s).
@ast
Switching to a protease inhibi ...... S clinical trial group 5125s).
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Switching to a protease inhibi ...... S clinical trial group 5125s).
@en
P2093
P2860
P304
P31
P356
10.1097/QAI.0B013E318042E204
P407
P433
P478
P50
P577
P698
P932